Other Deal Trends 2026: Activity Surges 3400% in 6 Months

Thirty-four deals in six months, up from zero in the prior period — that's a 3400% surge in other deal activity between the February–August 2026 window compared to August 2025–February 2026. This isn't a rounding error or a data artifact. Big Pharma is aggressively acquiring enabling technology platforms, tools companies, and non-traditional therapeutic assets at a pace that signals a fundamental reallocation of BD capital away from pure-play therapeutic licensing toward the infrastructure layer of drug development.

The Data — Other Deal Activity, Period over Period

The jump from literally zero recorded deals to 34 deserves scrutiny. Part of this reflects improved classification — Ambrosia's Deal Benchmarks platform now captures tools, reagent, and platform deals that previously fell outside traditional licensing taxonomies. But the signal is real. The dollar volumes are staggering: Merck KGaA alone committed $11.3 billion to acquire Bio-Techne, a deal that would have dominated headlines in any therapeutic area. This is not a category you can afford to ignore.

What's Driving the Trend

Strategic, not regulatory. The surge in other licensing 2026 activity is not being driven by FDA catalysts or competitive pipeline crowding. It's being driven by Big Pharma's realization that owning enabling platforms — protein engineering, AI-driven molecule generation, biologics reagent supply — creates durable competitive moats that individual drug assets cannot. Merck KGaA's acquisition of Bio-Techne is the clearest articulation of this thesis: control the tools layer and you control optionality across every therapeutic program downstream. This is vertical integration logic applied to biopharma R&D, and it's accelerating.

The second driver is AI-native drug design moving from speculative to transactional. Novartis's deal with Generate:Biomedicines — terms undisclosed, which itself tells you something about how early and strategic this bet is — reflects a willingness to pay for generative biology platforms before they produce late-stage clinical proof. Two years ago, these partnerships were option-like. Now they're being structured as acquisitions or deep co-development alliances. The implication is clear: pharma buyers believe the platform risk has materially decreased.

Third, capital availability is selectively abundant. While Series A and B rounds in biotech remain constrained, Big Pharma balance sheets are flush. Pfizer's $150M upfront to YaoPharma — with $2.05B in total deal value — shows that companies sitting on post-COVID cash reserves and facing LOE cliffs in the late 2020s are deploying capital into non-traditional categories where competition for assets is lower and valuations are, paradoxically, less inflated than in oncology or immunology.

Notable Deals

Merck KGaA / Bio-Techne ($11.3B): This is the deal that defines the category. Merck KGaA is paying a full cash price — upfront equals TDV — for a tools and reagents company. No milestones, no earnouts, no risk-sharing. That structure tells you Merck KGaA views Bio-Techne as a known asset with quantifiable revenue, not a bet on future clinical outcomes. The multiple entries in the deal table reflect reporting across announcement, amendment, and closing dates — this deal was clearly complex and evolved over June. At $11.3B, this is one of the largest non-therapeutic acquisitions in biopharma history. It sets a new ceiling for tools company valuations and will pull comparable company multiples upward.

Pfizer / YaoPharma ($150M upfront, $2.05B TDV): This deal has a more traditional licensing structure — 7.3% upfront-to-TDV ratio — suggesting milestone-heavy terms with commercial-stage triggers. The China-to-global licensing pathway has been gaining traction, and Pfizer's willingness to structure a $2B deal with a Chinese partner in the current geopolitical environment signals confidence in the asset and, more broadly, in cross-border deal architecture surviving regulatory headwinds.

Novartis / Generate:Biomedicines (undisclosed): The absence of financial terms is notable. This is almost certainly an early-stage platform partnership or equity-linked collaboration. Novartis has been systematically building its AI-native drug design capabilities, and Generate:Biomedicines — with its generative protein design engine — fits squarely into that strategy. Watch for this to be restructured into a larger acquisition within 18 months if initial programs hit IND-enabling milestones.

What This Means for BD Teams Right Now

If you're a tools or platform company, this is a seller's market — but only if you have scale. The Bio-Techne deal proves that Big Pharma will pay strategic premiums for established, revenue-generating platform businesses. But the key word is established. Early-stage tools companies without $200M+ in revenue are unlikely to command these multiples. The actionable move: if you're a mid-stage platform company, accelerate your commercial traction before approaching acquirers. Use Solidus to benchmark your valuation against the Bio-Techne precedent.

If you're a Big Pharma BD team, the window is narrowing. Thirty-four deals in six months means the best platform assets are getting picked off. The competitive set for enabling technology acquisitions is small — there are maybe 15-20 companies globally with the profile Merck KGaA targeted in Bio-Techne. Every month you delay, your options shrink and your cost of entry rises. Move now or accept that you'll pay a 30-40% premium in 12 months.

Deal structures are splitting into two modes: full-cash acquisitions for scaled platforms (Bio-Techne) and milestone-heavy licensing for earlier-stage or geography-specific assets (YaoPharma). Earnouts and CVRs are notably absent from this dataset, which suggests buyers are either going all-in or structuring conventional milestone waterfalls. Hybrid structures — equity stakes with co-development rights — are likely emerging in undisclosed deals like the Novartis/Generate:Biomedicines partnership.

For investors: the other deal trends 2026 data makes a compelling case for portfolio rebalancing toward enabling technologies. The multiple compression in pure-play therapeutic biotech is real; the multiple expansion in tools and platforms is equally real. The arbitrage opportunity exists today but won't last through 2027.

Benchmark your deal against current market rates using the Ambrosia calculator — whether you're structuring an acquisition, negotiating a platform license, or evaluating a tools company for your portfolio. The data has shifted. Your deal terms should reflect it.